Sponholz S, Bölükbas S, Schirren M, Oguzhan S, Kudelin N, Schirren J
Klinik für Thoraxchirurgie, Dr. Horst Schmidt Klinik, Helios Kliniken Gruppe, Ludwig-Erhard-Straße 100, 65199, Wiesbaden, Deutschland.
Chirurg. 2016 Feb;87(2):151-6. doi: 10.1007/s00104-015-0024-x.
The resection of liver and lung metastases from colorectal cancer has not yet been completely investigated. The aim of this study was to investigate the overall survival and prognostic factors for patients with liver and lung metastases from colorectal cancer.
A retrospective review of a prospective database of 52 patients with liver and lung metastases from colorectal cancer, undergoing metastasectomy with curative intent from 1999-2009 at a single institution was carried out.
The mean overall survival (OS) was 64 months. For synchronous liver and lung metastases the mean overall survival was 63 months (5-year survival 54 %) and for metachronous liver and lung metastases 74 months (5-year survival 58 %, p = 0.451). A poor prognostic outcome was observed in cases of localization of the primary tumor in the rectum (OS 81 vs. 38 months, p = 0.004), with multiple lung metastases (≥ 2 metastases, OS 74 vs. 59 months, p = 0.032) and with disease progression after premetastasectomy chemotherapy (OS 74 vs. 63 vs. 15 months, p < 0.001). No influence on overall survival was detected for bilateral lung metastases, thoracic lymph node metastases, disease recurrence and disease-free interval < 36 months.
Metastasectomy for liver and lung metastases of colorectal cancer is associated with a good overall survival in selected cases. Patients with liver and lung metastases should not be routinely excluded from metastasectomy and patients with thoracic lymph node metastases should also not be routinely excluded. Negative prognostic factors for survival are localization of the tumor in the rectum, multiple metastases and disease progression after premetastasectomy chemotherapy. Patients with disease progression after premetastasectomy chemotherapy should be excluded from metastasectomy.
结直肠癌肝肺转移灶的切除尚未得到充分研究。本研究旨在探讨结直肠癌肝肺转移患者的总生存期及预后因素。
对1999年至2009年在单一机构接受根治性转移灶切除术的52例结直肠癌肝肺转移患者的前瞻性数据库进行回顾性分析。
平均总生存期(OS)为64个月。同时性肝肺转移患者的平均总生存期为63个月(5年生存率54%),异时性肝肺转移患者为74个月(5年生存率58%,p = 0.451)。原发肿瘤位于直肠的患者预后较差(OS分别为81个月和38个月,p = 0.004),有多个肺转移灶(≥2个转移灶,OS分别为74个月和59个月,p = 0.032)以及转移灶切除术前化疗后疾病进展的患者预后较差(OS分别为74个月、63个月和15个月,p < 0.001)。双侧肺转移、胸段淋巴结转移、疾病复发以及无病间期<36个月对总生存期无影响。
在某些特定病例中,结直肠癌肝肺转移灶切除术与较好的总生存期相关。不应常规排除结直肠癌肝肺转移患者的转移灶切除术,胸段淋巴结转移患者也不应常规排除。生存的负面预后因素包括肿瘤位于直肠、多发转移以及转移灶切除术前化疗后疾病进展。转移灶切除术前化疗后疾病进展的患者应排除在转移灶切除术之外。